Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America  by Rodríguez-Noriega, Eduardo et al.
International Journal of Infectious Diseases 14 (2010) e560–e566Review
Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America
Eduardo Rodrı´guez-Noriega a,*, Carlos Seas b, Manuel Guzma´n-Blanco c, Carlos Mejı´a d,
Carlos Alvarez e, Luis Bavestrello f, Jeannete Zurita g, Jaime Labarca h, Carlos M. Luna i,
Mauro J.C. Salles j, Eduardo Gotuzzo b,1
aHospital Civil de Guadalajara, Fray Antonio Alcalde, Instituto de Patologı´a Infecciosa y Experimental, Centro Universitario Ciencias de la Salud,
Universidad de Guadalajara, Jalisco, Mexico
bUniversidad Peruana Cayetano Heredia, Lima, Peru
cCentro Me´dico de Caracas, Caracas, Venezuela
dHospital Roosevelt, Guatemala City, Guatemala
eHospital San Ignacio and Pontiﬁcia Universidad Javeriana, Bogota´, Colombia
fClinica Ren˜aca, Vin˜a Del Mar, Chile
gHospital Vozandes, Quito, Ecuador
h Pontiﬁcia Universidad Cato´lica de Chile, Santiago, Chile
iUniversidad de Buenos Aires, Buenos Aires, Argentina
jHospital Irmandade da Santa Casa de Miserico´rdia de Sa˜o Paulo, Sa˜o Paulo, Brazil
A R T I C L E I N F O
Article history:
Received 18 December 2008
Received in revised form 22 May 2009
Accepted 25 August 2009







S U M M A R Y
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a prominent nosocomial bacterial
pathogen, associated with signiﬁcant morbidity and mortality. The global incidence is increasing, and
Latin America is no exception. This article reviews MRSA clonal distribution in Latin America and
implications for clinical practice.
Design: A PubMed literature search (1966–2008) identiﬁed 32 articles that characterizedMRSA clones in
Latin America.
Results: Data from these articles show that since 1990, several epidemic MRSA clones have spread in
Latin America. The multidrug-resistant Brazilian clone is widespread, especially in Brazil and Argentina,
but more recently clones with susceptibility to a range of antibiotics have been detected in Brazil,
whereas in Argentina, as in Chile, Colombia and Paraguay, the multidrug-resistant Cordobes/Chilean
clone prevails. In Mexico, the New York/Japan clone is most frequent. Data were not available from every
country and, despite the increasing prevalence of communityMRSA infections, most were collected from
tertiary care centers.
Conclusions: A variety of epidemic MRSA clones are circulating in Latin America, some of which harbor
genes that encodemultidrug resistance or enhanced pathogenicity. Continued collection and reporting of
epidemiological data is crucial for effective prevention and treatment.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Methicillin-resistant Staphylococcus aureus (MRSA) clones
have emerged to cause a global public health concern.1–7 Several
major pandemic MRSA clones have been identiﬁed around the
world, but despite one such clone having originated in Brazil, the
molecular epidemiology of MRSA in Latin America is largely
unknown.8* Corresponding author. Tel.: +52 33 3614 5568; fax: +52 33 3685 0501.
E-mail address: idfcolima@yahoo.com (E. Rodrı´guez-Noriega).
1 The authors or this review are all members of the Latin American Working
Group on Gram Positive Resistance.
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.08.0181.1. Analysis of the relatedness of clones
MRSA clones (bacterial strains descended from a common
ancestor) diversify through point mutations, recombination, or the
acquisition/deletion of mobile genetic elements, giving rise to
extensive genomic and phenotypic diversity. Discriminating and
reproducible typing methods are needed to study the epidemiology
of MRSA. Frequently used methods include ribotyping, pulsed-ﬁeld
gel electrophoresis (PFGE), andpolymerasechainreaction(PCR)with
repetitive element primers, but these methods are inherently prone
toproducedifferent results indifferent laboratories due to thehighly
variable, rapidly evolving bacterial genome regions that they target.
PFGE has commonly been used in studies of MRSA epidemiology in
Latin America, to show the relatedness of isolates from recent
outbreaks. However, the technique is not well-suited to long-termses. Published by Elsevier Ltd. All rights reserved.
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procedure to decipher gene variations that accumulate slowly.
Newermolecular typingmethods, includingmultilocus enzyme
electrophoresis (MLEE) and multilocus sequence typing (MLST),
are highly discriminatory and easily reproducible. MLST is used to
characterize isolates of bacteria and distinguish between clones by
targeting the sequences of internal fragments of housekeeping
genes, where genetic variations develop gradually.9,10 MLST allows
related strains recovered in different countries to be readily
identiﬁed. When MLST results are analyzed using an algorithm
known by the acronym BURST (Based Upon Related Sequence
Types), groups of isolates with a deﬁned level of similarity in allelic
proﬁle can be discerned among large MLST datasets, and a
dendrogram can be constructed.6,7 BURST has been useful in
studying the evolutionary history of MRSA, to predict the ancestral
allelic proﬁle (genotype) of each clonal complex (CC), and the
pattern of evolutionary descent of all isolates in the group.6,11
1.2. Historical origins and mechanisms of evolution of MRSA
The ﬁrst MRSA clones had similar genetic and phenotypic
properties to methicillin-susceptible Staphylococcus aureus (MSSA)
clones that were epidemic in the early 1960s in Europe.4 The initial
appearance of MRSA resulted from the acquisition by successful
MSSA clones of mecA, the gene that encodes a penicillin-binding
protein conferring resistance to methicillin, from an unknown
heterologous source.4 The mobile genetic element that carries
mecA, called the staphylococcal cassette chromosome mec
(SCCmec) has ﬁve forms (I, II, III, IV and V), which have arisen
by the horizontal transfer of mecA in independent events.6,12
Five major lineages of MRSA (CC5, CC8, CC22, CC45 and CC30)
circulate internationally and cause most nosocomial MRSA
infections worldwide.5,11,13–15 Within each lineage, putative
evolutionary pathways have been proposed by Robinson and
Enright,11 based on sequence types (ST) characterized by MLST. A
relatively small number of pandemic MRSA clones have caused a
majority of MRSA infections. Five predominant clones (Brazilian,
Iberian, Hungarian, pediatric and New York/Japan (NYJ) clones)
were identiﬁed among 3000MRSA strains collected in surveillance
studies and outbreak investigations from 1994 to 2000 (the
CENMET initiative); PFGE was used to characterize these strains.3
These ﬁve clones accounted for 68% of isolates. The authors
hypothesized that these major clones have a unique ability to cope
with changing clinical environments.Figure 1. Evolution of MRSA clones in Latin American countries: time line to show wh
B = BrazilianMRSA clone and variants; C = Cordobes/ChileanMRSA clone; CA = CMRSA-6
M =Mexican MRSA clone; MW2 = MW2-related MRSA clone; NY/J = New York/Japan-re
MRSA clone; U = Uruguayan hospital MRSA clone; UR6 = Uruguayan community outbrea
Australia 1 MRSA clone.
*First identiﬁcation of Brazilian MRSA isolates with vancomycin and teicoplanin heteroGathering accurate data about the distribution and evolution of
these clones in the Latin American region is necessary to support
the use of treatments effective against themost prevalent clones in
each local region. Such data also provide insight into possible
mechanisms of dissemination across Latin America and help to
explain the predominance of certain clones over others, an
understanding of which may guide strategies to control the
spread of MRSA. Evaluation of existing epidemiological data is also
useful for predicting future trends. By summarizing available data
on the clonal distribution of MRSA within Latin America, we hope
to promote awareness of local differences in epidemiology that
impact on the success of prevention and treatment protocols, and
thereby encourage more effective infection control and rational
use of antibiotics in the region.
2. Evolution of MRSA in Latin America
We performed a literature search to evaluate the history and
distribution of MRSA clones within Latin America. The PubMed
database was searched for the years 1966–August 2008 for
published articles relating to the clonal evolution of MRSA in Latin
America. Search terms were: ‘MRSA clones’, ‘Methicillin-resistant
Staphylococcus aureus clones’, ‘Latin America’, and ‘Country name’
(country names were Argentina, Bolivia, Brazil, Chile, Colombia,
Costa Rica, Cuba, Dominican Republic, Ecuador, Guatemala,
Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay,
and Venezuela).
Most of the pertinent, published data onMRSA in Latin America
come from only eight countries. Twenty-nine relevant published
articles reporting data collected from single Latin American
countries were included: 18 from Brazil (1994–2008), six from
Argentina (1998–2008), two from Colombia, two fromMexico and
one from each of Uruguay, Paraguay, and Trinidad and Tobago. A
further three published studies evaluated MRSA clones collected
from several countries: Brazil, Argentina, Uruguay, Mexico and
Chile;16 Brazil and Argentina17 and Brazil and Uruguay.18
Additionally, recent data were obtained from Chile19,20 and the
Colombian–Caribbean region.21,22
Figure 1 shows the sequence of MRSA clonal evolution and
dissemination across Latin America, as it is known from the
available published data.8,16–50 Most of the MRSA clones circulat-
ing in Latin America are related to the ﬁve major MRSA
international clones: NYJ, pediatric, Brazilian, Iberian, and Hun-
garian (Figure 2).8,16–37,39–50ere and when clones were isolated.8,16–50
(CanadianMRSA clone); H = HungarianMRSA clone; I = Iberian-relatedMRSA clone;
lated MRSA clone; P = pediatric-related MRSA clone; O = Oceania Southwest Paciﬁc
k MRSA clone; U3 = USA-300 MRSA clone; U8 = USA-800 MRSA clone; W =Western
geneous resistance (1996–1998).
Figure 2. Relationship of Latin American MRSA strains to clonal complexes (CC5, CC8 and CC30) and international MRSA clones according to the model put forward by
Robinson and Enright (2003).11
Major international clones are indicated in bold type. Sequence types (ST) and SCCmec types (I to IV and variants) of MRSA clones are indicated where known. Reference
numbers are shown in superscript. No Latin American isolates belonging to CC22 or CC45 were described. UR6 = Uruguayan community outbreak MRSA clone;
OSPC = Oceania Southwest Paciﬁc MRSA clone; WA1 =Western Australia 1 MRSA clone.
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Twenty studies described clonal MRSA in Brazil (Figure 3).8,16–
18,23–25,27–30,34,37,40,42,43,46–48,50 The earliest publication fromBrazil
described the inter-hospital spread of a single MRSA clone in eight
of nine hospitals under surveillance in Sao Paulo between 1990 and
1992.8 A year later, MRSA isolates collected from ﬁve large
teaching hospitals in different parts of Brazil shared a common
PFGE pattern, again indicating that a single, epidemic clone (the
‘Brazilian’ clone) was widespread in Brazil.24 Since then, the
Brazilian clone and related variants, collectively termed the
‘Brazilian epidemic clonal complex’ (BECC),28 have been highly
prevalent in Brazilian hospitals each year between 1990 and 2004
(Figure 3). In recent studies of nosocomial MRSA isolates in
Brazil,42,46 the frequency of BECC clones has remained above 50% of
all S. aureus isolates.
The BECC MRSA clones have acquired multi-resistance genes,
and isolates have demonstrated resistance to chloramphenicol,
cephalothin, ciproﬂoxacin, clindamycin, erythromycin, gentami-
cin, lincomycin, penicillin, tetracycline and trimethoprim–sulfa-
methoxazole (TMP–SMX).2,24 In 1999, the acquisition of a novel
mupirocin resistance gene (ileS) was described.29 As many as 74%
of Brazilian clone isolates from teaching hospitals in Brazil
between 1992 and 1994 were reported to be sensitive only to
vancomycin,24 and this pattern of resistance was also observed in
isolates collected in other studies.17,25,27–29 The emergence of a
subpopulation of BECC isolates with vancomycin and teicoplanin
heterogeneous resistance in the northeast of Brazil was observed in
1996–1998.30In addition to multi-resistance, isolates of the predominant
BECC variant that were collected between 1995 and 1998 in Bele´m,
developed an enhanced ability to produce bioﬁlm on inert
polystyrene surfaces and to adhere to and invade epithelial airway
cells.28 In another study in Rio de Janeiro, BECC isolates had
acquired the gene for production of Panton–Valentine leukocidin
(PVL) toxin, which was suggested to have occurred by horizontal
transfer from a reservoir of PVL-positive MSSA isolates.34
Although BECC MRSA clones are widespread in Brazil, other
clones are also in circulation. In Rio de Janeiro in 1999–2000, the
Brazilian clone coexisted with other clones, one resembling the
Hungarian clone and one similar to the pediatric clone.34 In 2004, a
gentamicin-susceptible MRSA clone resembling the NYJ MRSA
clone was reported in the same city.47 Other nosocomial MRSA
strains have been described with susceptibility to four or more
antimicrobials and harboring SCCmec type IV – traits that are
usually associated with community-associated MRSA (CA-
MRSA).51 This suggests that CA-MRSA clones have been introduced
into the hospital and are now circulating as nosocomial pathogens.
In 2007, non-multiresistant MRSA isolates were identiﬁed in
hospitals in two cities in Brazil;42 these caused severe nosocomial
infections and displayed PFGE patterns similar to USA-800, with a
high growth rate, an ability to produce bioﬁlm, and enterotoxin
genes. International CA-MRSA strainswith genes encoding PVL and
enterotoxin have been identiﬁed in Rio de Janeiro and Porto Alegre,
causing both community- and hospital-acquired infections.43,48
Conversely, MRSA strains isolated within 6 h of hospital
admission from the nasopharyngeal passages of 686 Brazilian
children between 2000 and 2001 were multidrug-resistant and
Figure 3. Distribution and dissemination of MRSA clones in Latin American countries and the Caribbean.
Shading indicates the dissemination of the Brazilian clone. Datawere not available for countries shaded in dark gray. Reference numbers are shown in superscript. Underlined
text shows multidrug-resistant clones.
yIncludes isolates from community-acquired infection or colonization.
MW2 = MW2-relatedMRSA clone; NY/J = New York/Japan-relatedMRSA clone; OSPC = Oceania Southwest PaciﬁcMRSA clone; UR6 = Uruguayan community outbreakMRSA
clone; WA1 =Western Australia 1 MRSA clone.
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of hospital origin were now spreading in the community.37
2.2. Argentina
Eight studies described the clonal epidemiology of MRSA in
Argentina (Figure 3).16,17,26,33,36,39,45,49 The presence of the
Brazilian clone was conﬁrmed,16,17,26 but over time an increasing
proportion of other epidemic clones have been detected.
The year 2002 marks the ﬁrst published report of the Cordobes/
Chilean clone, co-existing with the Brazilian clone in the second
largest city in Argentina.33 Of isolates collected in 1999 from six
hospitals in Co´rdoba, 34% were the Brazilian clone and 38% of
isolates belonged to a major clonal type with a novel PFGE pattern
(later found to be closely related to the Chilean clone).16,33 Most
Cordobes/Chilean clone isolates had a multiresistant phenotype,
although the resistance proﬁle differed between subtypes and all
were susceptible to TMP–SMX and minocycline. This clone caused
outbreaks of nosocomial infection in Co´rdoba and Buenos Aires,
and its prevalence increased over time.33,36,39,45,49
Variants of the pediatric clone were detected in Buenos Aires,
Tucuma´n and Co´rdoba in the late 1990s.26,33,39,49 In Co´rdoba,
isolates related to the pediatric clone were associated with a new
variant SCCmec element, type IVNv.33,39,49 Most of these were
resistant to b-lactam antibiotics and gentamicin, and by 2001,
most were also resistant to rifampin. The clone caused approxi-mately 15% of nosocomial infections and a variable proportion of
community-acquired infections.33,39,49 Related clones (ST5-MRSA-
SCCmec IVa or IVc) were the most frequent CA-MRSA isolates
detected in 2005–2006, and some harbored genes for PVL and
enterotoxin A.49
2.3. Other Latin American countries and the Caribbean
We identiﬁed 13 published studies from other Latin America
countries and the Caribbean (Figure 3).16,18–22,31,32,35,38,41,44,50 In
Chile, Aires de Sousa et al.16 detected a variant of the Brazilian
clone, existing together with a novel clone, the Chilean clone
(known later as the Cordobes/Chilean clone, mentioned above).
Recent data presented in Chile showed that the Cordobes/Chilean
clone has become the predominant clone.19,20
The ﬁrst report from Colombia found that MRSA isolates from
ﬁve hospitals in Bogota´ (1996–1998) had 80% genetic homology to
the pediatric clone, although these isolates were recovered from
patients of all ages and had a multiresistant phenotype.31
However, later studies detected the Cordobes/Chilean clone in
Colombia between 2001 and 2006,22,41 and Espinal et al.21
observed this clone among clinical isolates recovered in the
Colombian–Caribbean region. It is of note that Buitrago et al.
observed that isolates with the characteristics of CA-MRSA strains
were increasing in prevalence in Colombia between 2001 and
2006.22
E. Rodrı´guez-Noriega et al. / International Journal of Infectious Diseases 14 (2010) e560–e566e564The Cordobes/Chilean clone was also the predominant clone in
Paraguay in 2005, where it co-existed with the Brazilian clone.50
Aires de Sousa et al.16 detected a unique clone associated with
pediatric infections in Mexico, resistant to penicillin, oxacillin, and
gentamicin. This Mexican clone predominated in Mexico City
between 1997 and 2000, but was entirely substituted by the
multidrug-resistant NYJ clone by 2002.32 Isolates collected
between 1999 and 2003 in Guadalajara were also similar to the
NYJ clone.35
In Trinidad and Tobago, the Canadian MRSA clone, CMRSA-6,
was detected in three major hospitals between 2000 and 2001, a
possible result of dissemination through tourism.38
Between 1996 and 1998, Aires de Sousa et al. demonstrated
the presence of the Brazilian clone in Uruguayan hospitals (100%
of MRSA isolates),16 and this clone was also detected in four of
ﬁve hospitals in Montevideo by Senna et al.,18 although it only
predominated in one hospital. The large outbreak of community
infections caused by MRSA in Montevideo in 2002–2003 was
associated with a novel clone, UR6, although other CA-MRSA
strains were also identiﬁed.44 The highly virulent nature of these
CA-MRSA clones is associated with the production of PVL
toxin.44
3. Discussion
The introduction of methicillin and other antibiotics has
provided a selective pressure for the evolution of new and diverse
MRSA clones, which have spread in countries around the world,1
and Latin America has been no exception. In this review, we have
found that the pandemic Brazilian clone and variants continue to
circulate throughout hospitals in Brazil and are also disseminated
in neighboring countries. Several other clones have been detected
in the region and in particular, clones related to the NYJ and the
pediatric clones, belonging to CC5, have successfully spread. The
Cordobes/Chilean clone was ﬁrst detected in isolates from Chile in
1997, and in Argentina in 1999; this quickly became the
predominant clone in Argentina, Chile, Colombia and Paraguay.
The NYJ clone has been detected in Brazil, and has completely
displaced the Mexican clone in certain Mexican hospitals. Variants
of the pediatric clone have caused infections in the healthcare
setting or the community in Brazil, Argentina and Colombia.
Several studies characterized clones involved in MRSA infections
acquired in the community. CA-MRSA clones in Brazil, Argentina,
Colombia, and Uruguay belonged to CC5, CC8 and CC30, and were
found to be related to CA-MRSA clones previously described in the
USA andWestern Australia. Adding to these data, a recent study by
Goering and colleagues52 identiﬁed the hospital-associated MRSA
(HA-MRSA) strain, USA-800, in Peru and Costa Rica, and the CA-
MRSA strain, USA-300, in Costa Rica.
A combination of factors may have caused the observed pattern
of MRSA clones in Latin America. In 1998 Aires de Sousa et al.13
demonstrated the intercontinental spread of the Brazilian clone
between Brazil and Portugal, and the NYJ clone has also been
disseminated between continents, causing infections in New York
City, New Jersey, Connecticut, and Pennsylvania, as well as in
Tokyo, Japan,14 and now in Latin America. Explanations for this
phenomenon, which could also apply in Latin America, were
suggested to include the increased migration of human popula-
tions, including healthcare professionals, combined with ineffec-
tive practices to control the spread of MRSA from infected or
colonized patients.13
Antibiotic selection may be a key factor causing the dissemina-
tion of predominantMRSA clones in hospitals.53 In the community,
other factorsmay bemore inﬂuential. In Latin America, the SCCmec
element, type IV, has been detected in several clones circulating in
the community and in the healthcare setting. Previous analyseshave found that this smallest SCCmec element is the most
frequently acquired, suggesting that it may transfer most
efﬁciently or be selectively favored over the larger, more complex
elements, and this property is likely to impact on the future
evolution of MRSA.11
MRSA clones with enhanced pathogenic properties have
important implications for infection control and treatment
strategies. The presence of new virulence factors in MRSA in Latin
America is a worrisome trend. Virulence factors may promote
attachment and persistence, evasion of defense mechanisms, or
tissue invasion and penetration, as well as enabling the production
of toxins that mediate more aggressive disease (e.g., toxic shock
syndrome).54 These developments are a signiﬁcant concern,
especially because transfer of virulence genes has been observed
between HA- and CA-MRSA strains.55 Such virulence genes may be
acquired by epidemic MRSA clones to produce new variants with
enhanced pathogenesis, a situation that has already been observed
in Brazil. As well as harboring genes encoding PVL toxin, a toxin
capable of destroying cells, the Brazilian clone has also demon-
strated the potential for acquisition of genes for production of
bioﬁlm.28,34
S. aureus can rapidly develop resistance to antibiotics. In 2008,
more than 90% of S. aureus isolates were resistant to penicillin, the
incidence of MRSA in Latin America was greater than 50% of all S.
aureus isolates in some countries,56 and strains were found to be
prone to develop resistance to additional antibiotics. The Brazilian
clone is usually multidrug-resistant and in some cases sensitive
only to vancomycin, tigecycline, linezolid and daptomycin; this
clone can also develop mupirocin resistance and heterogeneous
vancomycin and teicoplanin resistance. The pediatric clone has
developed multidrug resistance in some regions of Latin America.
The Cordobes/Chilean clone and the NYJ clones are also multidrug-
resistant (although both are sensitive to glycopeptides and
linezolid, and the Cordobes/Chilean clone is usually susceptible
to TMP–SMX, minocycline and rifampin, while the NYJ clone is
usually susceptible to TMP–SMX, gentamicin and rifampin). Since
there are currently few options available for the treatment of
multidrug-resistant MRSA infections, clinicians around Latin
America should be prudent in using these antibiotics.
Both S. aureus and MRSA can colonize the anterior nares, axilla,
groin, and the gastrointestinal tract.54 More than 20% of humans
have either persistent or intermittent nasal colonization with
MRSA. From the colonized sites, S. aureus and MRSA can cause
infection or be transmitted to other persons. A carrier of S. aureus or
MRSA is at potential risk, especially when admitted to hospital, of
developing an infection involving the colonizing pathogen and of
transmitting the MRSA to other patients with risk factors for
infection. The need to prevent S. aureus/MRSA-colonized patients
from entering hospital and causing dissemination of the pathogen
has led to the publication of guidelines for what is now known as
universal surveillance for MRSA.57 Despite most Latin American
countries using infection control practices based on the Centers for
Disease Control and Prevention (CDC) guidelines, and with some
institutions having an antibiotic stewardship program based on
guidelines from the Infectious Diseases Society of America,58 using
mostly education, streamlining of therapy, and intervention and
feedback (also known as a ‘back-end’ approach), MRSA continues
to be a major problem.
Our understanding of the molecular epidemiology of MRSA in
Latin America remains limited. So far, data have mainly been
collected from large tertiary hospitals. Few studies have collected
isolates from the community setting, despite evidence that the
incidence of CA-MRSA is increasing.22 Epidemiological data are not
published frequently from every hospital, and therefore it is
difﬁcult to follow evolving trends, and in some countries there are
no published data.
E. Rodrı´guez-Noriega et al. / International Journal of Infectious Diseases 14 (2010) e560–e566 e565The efforts of Latin American investigators are important, and
rigorous surveillance is needed in order to prevent further
problems caused by MRSA clones. Continuing surveillance,
molecular epidemiological studies, and timely dissemination of
the ﬁndings in our region are vital.
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